Zacks Investment Research downgraded shares of Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) from a buy rating to a hold rating in a research note issued to investors on Wednesday.

According to Zacks, “Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “

Several other equities analysts have also weighed in on DRNA. Cowen and Company reissued a buy rating on shares of Dicerna Pharmaceuticals in a report on Sunday, June 26th. Stifel Nicolaus reduced their price objective on Dicerna Pharmaceuticals from $16.00 to $13.00 and set a buy rating for the company in a report on Thursday, June 30th. Chardan Capital reduced their price objective on Dicerna Pharmaceuticals from $5.00 to $4.00 and set a neutral rating for the company in a report on Thursday, June 30th. Finally, Leerink Swann reissued a buy rating on shares of Dicerna Pharmaceuticals in a report on Thursday, June 30th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Dicerna Pharmaceuticals has a consensus rating of Buy and a consensus price target of $12.30.

Analyst Recommendations for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) traded down 2.57% on Wednesday, hitting $5.31. The company had a trading volume of 50,314 shares. The company’s market capitalization is $110.20 million. Dicerna Pharmaceuticals has a 12-month low of $2.69 and a 12-month high of $15.93. The firm has a 50-day moving average price of $3.81 and a 200 day moving average price of $3.91.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.75) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.84) by $0.09. Equities analysts expect that Dicerna Pharmaceuticals will post ($3.17) EPS for the current year.

A number of large investors have recently bought and sold shares of the stock. FMR LLC raised its stake in Dicerna Pharmaceuticals by 0.4% in the second quarter. FMR LLC now owns 3,108,916 shares of the biopharmaceutical company’s stock valued at $9,327,000 after buying an additional 11,719 shares in the last quarter. RTW Investments LLC raised its stake in Dicerna Pharmaceuticals by 2.6% in the first quarter. RTW Investments LLC now owns 2,026,894 shares of the biopharmaceutical company’s stock valued at $10,864,000 after buying an additional 51,665 shares in the last quarter. Oxford Asset Management raised its stake in Dicerna Pharmaceuticals by 109.3% in the second quarter. Oxford Asset Management now owns 286,413 shares of the biopharmaceutical company’s stock valued at $859,000 after buying an additional 149,560 shares in the last quarter. State Street Corp raised its stake in Dicerna Pharmaceuticals by 20.7% in the first quarter. State Street Corp now owns 209,015 shares of the biopharmaceutical company’s stock valued at $1,123,000 after buying an additional 35,820 shares in the last quarter. Finally, Opus Point Partners Management LLC raised its stake in Dicerna Pharmaceuticals by 8.0% in the first quarter. Opus Point Partners Management LLC now owns 108,000 shares of the biopharmaceutical company’s stock valued at $579,000 after buying an additional 8,000 shares in the last quarter. 62.38% of the stock is owned by institutional investors.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

5 Day Chart for NASDAQ:DRNA

Receive News & Stock Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.